相关实验视频
Updated: Jul 12, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
用于免疫检查点降解疗法的DNA适合剂激活的共价LYTAC
Yuqing Li1, Xueliang Liu2, Lu Yu2,3
1Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou 215123, China.
新的 lysosome-targeting chimera (LYTAC) 疗法降低了免疫检查点 PD-L1,从而增强了抗瘤反应. 与抗体疗法相比,这种共价LYTAC方法提供了更好的疗效和减少了炎症.
科学领域:
- 生物技术
- 免疫学
- 癌症治疗
背景情况:
- 免疫检查点阻塞 (ICB) 疗法显示出有前途,但反应率有限.
- 编程死亡连接体-1 (PD-L1) 是癌症的一个关键免疫检查点目标.
研究的目的:
- 开发一种新的免疫检查点降解 (ICD) 疗法,使用 lysosome-targeting chimera (LYTAC) 来消耗PD-L1.
- 在体内评估共价LYTAC系统对PD-L1降解的有效性和安全性.
主要方法:
- 针对PD-L1和 lysosome-trafficking受体的基于嵌合体的共价LYTAC的设计.
- 在体内评估PD-L1降解效率和 lysosomal trafficking
- 与ICB治疗相比,抗瘤疗效,免疫性亡诱导和炎症损伤的评估.
主要成果:
- 在体内实现了有效的PD- L1降解和 lysosomal trafficking.
- 由LYTAC诱导的PD- L1衰竭消除了PD- 1/ PD- L1的免疫抵抗,并触发了免疫性瘤细胞亡.
- 使用共价LYTAC的ICD疗法具有可比或更高的抗瘤疗效,并减少了炎症副作用.
结论:
- 共价LYTAC是一种新且有效的免疫检查点降解策略.
- 这种平台比传统的ICB疗法具有优势,包括直接诱导瘤细胞亡和提高安全性.
- 开发的LYTAC技术有可能降解其他膜蛋白,并为临床应用推进基于DNA的药物.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....